Ariad Pharmaceuticals Inc.'s Iclusig (ponatinib) has been approved in Japan for second-line use in chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) through Asian licensee Otsuka Pharmaceutical Co. Ltd.
A 15 mg tablet formulation of the oral kinase inhibitor is indicated for CML patients resistant or intolerant to previous...